The Reason It Trades, Quarterly Results, Project Financing and Strategic Acquisitions – Research on Dominovas Energy, Priority Aviation, Elite Pharmaceuticals, PositiveID
NEW YORK, NY / ACCESSWIRE / October 29, 2015 / Moments ago, Trader's Choice released another issue of its world-class newsletter in which it took the time to review and explain some of the most talked about situations on wall street today: Dominovas Energy Corporation (OTC: DNRG), Priority Aviation, Inc. (OTC: PJET) Elite Pharmaceuticals Inc. (OTC: ELTP) and PositiveID Corporation (OTC: PSID).
Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full commentary is being made available to the public on a complimentary basis.
This release includes the following highlights:
DNRG from $0.01 on June 3, 2015 (+700% gain)
PJET from $0.0013 on September 22, 2015 (+46% increase)
ELTP from $0.07 on July 19, 2013 (now +300% higher)
PSID from $0.02 on May 4, 2015 (+75% momentum run)
Did you want to hear about these companies before their big move? Trader's Choice studies patterns of success to discover the Trade of the Year, before the run.
Get 2015's TRADE of the YEAR
(You may have to copy and paste the link into your browser)
1 Year FREE Subscription Link: http://www.Traders-Choice.com/2015free
Highlights from today's analysis includes:
On Wednesday, October 28, 2015, the U.S. markets finished stronger as NASDAQ ended at 5,095.69, up 1.30%, Dow Jones increased 1.13% to finish the day at 17,779.52, and the S&P closed at 2,090.35, up 1.18%.
- On June 3, 2015, Dominovas Energy was trading at $0.01 and has since experienced gains of 700%. Shares of Dominovas Energy Corporation jumped 224.16% to close Tuesday's session at USD 0.12. While oscillating between USD 0.06 and USD 0.12, the stock recorded a trading volume of 26.6 million shares. On the same day, Dominovas Energy announced a landmark capital commitment for USD 1.2 billion in project financing with Graecrest Energy Solutions. The Company informed that the financing will fund the initial phase to manufacture, produce, and deploy Dominovas Energy's proprietary RUBICON(TM) SOFC systems. Neal Allen, Chairman and CEO of Dominovas Energy commented, "This is an unprecedented and historic commitment not only for Dominovas Energy, but it is additionally significant for the fuel cell industry as a whole. This financing commitment is further validation of the Company's business model and an undeniable endorsement of the technical prowess of the RUBICON(TM) and the 'game plan' we have set forth for the commercial deployment of our fuel cell system." Dominovas Energy Vice President of Investments and Finance Eric Fresh added that under the terms of the commitment, Dominovas Energy can reassess its needs to potentially expand capital commitments, which will help in accommodating subsequent financing phases of RUBICON(TM) system deployments.
- On September 22, 2015, Priority Aviation, Inc. was trading for $0.0013. Since then, on Tuesday, shares in Priority Aviation, Inc. recorded a trading volume of 98.9 million shares, significantly higher than their 30-day average volume of 1.8 million shares. The stock surged 62.50% to end the session at USD 0.0026. Previously on August 11, 2015, Priority Aviation reported financial results for the second quarter ended June 30, 2015. The Company generated total gross aviation related revenues of USD 1.28 million for the quarter, as compared to USD 2.17 million for the same period in 2014. The change was largely due to Q2 2014 results reporting several large flights, including a single large charter flight of USD 716,000. Further, the Company stated that it successfully negotiated settlement of USD 237,750 of principal debt with a noteholder. Additionally, after extensive research, Priority Aviation wrote off USD 200,000 of additional convertible debentures due to dissolution of the noteholder. Further, the Company announced appointment of Arnon Epstein to the Board of Directors succeeding Jonah Meer. The release informed that Epstein has held corporate marketing and business development management positions in several leading international companies, including Procter and Gamble, Comverse and Radiancy. The Company further stated that it is searching for a new business focused in the technology sector.
- On July 19, 2013, Elite Pharmaceuticals Inc. was trading for $0.07 and has since risen 300%. Shares of Elite Pharmaceuticals Inc. ended Tuesday's session 1.44% higher at USD 0.28. While oscillating between USD 0.28 and USD 0.31 during the session, the stocks recorded a trading volume of 6.4 million shares. The company is trading at a P/E (TTM) multiple of 4.4x and a P/S multiple of 20.0x. In a press release dated August 10, 2015, Elite Pharmaceuticals announced results for the first quarter of fiscal 2016, ended June 30, 2015. The Company generated consolidated revenue of USD 7.1 million in Q1 FY 2016, an increase from USD 1.2 million reported in Q1 FY 2015. Revenues consisted of USD 5 million in milestone payments from the ELI-200 license to Epic Pharma and a record USD 2.1 million generated from product revenue. Gross profit for the period was recorded at USD 5.9 million, against USD 0.4 million in the prior year quarter. Further, net income of the Company amounted to USD 16.1 million, compared to net loss of 4.4 million in same period last year. Commenting on the results, Nasrat Hakim President and CEO, said, "I am extremely pleased with the record revenues and operating profit this quarter. I am also excited that Elite has completed dosing of the efficacy study required for the ELI-200 submission."
- On May 4, 2015, PositiveID Corp was trading for $0.02 and has since increased 75%. PositiveID Corp's stock edged up 1.89% to close Tuesday's session at USD 0.04. The stock recorded a trading volume of 13.7 million shares, which was much above its 30-day daily average volume of 4.4 million shares. The company is trading close to its 50-day moving average of USD 0.03. Recently on October 21, 2015, PositiveID Corporation, a developer of biological detection and diagnostics solutions, announced that it has entered into an agreement to acquire the capital stock of Thermomedics, Inc., which manufactures and markets the FDA-cleared Caregiver(R) non-contact clinical-grade thermometer. The Company informed that the acquisition is expected to strengthen its FDA and manufacturing capabilities, and enhance distribution channels into synergistic federal and commercial healthcare customers. William J. Caragol, Chairman and CEO of PositiveID, commented, "We believe that once completed, the acquisition of Thermomedics will bring an exciting product and management team to our portfolio as we continue toward commercialization of Firefly Dx. Not only will Caregiver provide additional revenue for PositiveID, we believe it will also provide opportunities to fight against the spread of disease, while providing a pathway to customers and delivering proven manufacturing and FDA expertise."
Why Trader's Choice?
"Give yourself an advantage in today's market."
"In order to become successful, you need to have information as it happens and understand how it plays out into future stock price. This is our expertise. We know what moves markets. We understand what makes a winner. We translate our extensive research and years of experience into easy-to-understand emails for our subscribers."
"Don't waste time trying to figure it out for yourself; tip the scales in your favor and add our experience to your team. Subscription to our complementary real-time newsletter is free for 1-year and instantly available at http://www.Traders-Choice.com/2015free."
About Trader's Choice:
Trader's Choice ("TC") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. TC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
TC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein. The information in this release has been sourced from a third party data base.
TC, the Author and the Reviewer (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.traders-choice.com/.
TC is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.
For any questions, inquiries, or comments reach out to us directly at:
E-mail: press (at) traders-choice.com
SOURCE: Trader's Choice